Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Jefferies Financial Group Inc. for possible violations of federal securities laws and unlawful business practices, particularly in relation to its exposure to First Brands' bankruptcy [1][2]. Investigation Details - The investigation is focused on whether Jefferies has engaged in unlawful business practices that may have harmed its stockholders [1][2]. - Jefferies disclosed that its asset management fund held approximately $715 million in receivables linked to First Brands, which is under scrutiny due to accounting irregularities [6]. Stock Impact - Following the news of First Brands' bankruptcy and Jefferies' exposure, Jefferies' stock price dropped by $4.66, or 7.9%, closing at $54.44 per share on October 8, 2025, resulting in losses for investors [6].

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Firefly Aerospace Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Company Financial Performance - Firefly conducted an initial public offering of 19.3 million shares at a price of $45.00 per share on August 7, 2025 [6] - For Q2 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter the previous year [6] - Revenue for Q2 2025 was reported at $15.55 million, which was below analyst estimates of $17.25 million and represented a 26.2% decline from the same quarter last year [6] - Following the financial results announcement, Firefly's stock price dropped by $7.58 per share, or 15.31%, closing at $41.94 per share on September 23, 2025 [6]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Firefly Aerospace Inc. regarding possible violations of federal securities laws and other unlawful business practices [1][2] Company Financials - Firefly conducted an initial public offering on August 7, 2025, issuing 19.3 million shares at a price of $45.00 per share [6] - For the second quarter of 2025, Firefly reported a loss of $80.3 million, or $5.78 per share, compared to a loss of $58.7 million, or $4.60 per share, in the same quarter the previous year [6] - The company's revenue for the second quarter was $15.55 million, which was below analyst estimates of $17.25 million and represented a 26.2% decline from the same quarter last year [6] - Following the financial results announcement, Firefly's stock price dropped by $7.58 per share, or 15.31%, closing at $41.94 per share on September 23, 2025 [6]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against CarMax, Inc. for possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The investigation is focused on whether CarMax has engaged in actions that could harm stockholders, particularly in light of recent financial performance [1][2] Financial Performance - On April 10, 2025, CarMax reported its fourth quarter and fiscal year 2025 results, missing consensus estimates and removing long-term revenue, unit sales, and market share goals due to macroeconomic factors, leading to a stock price drop of $13.61 (17%) to $66.45 [6] - On September 25, 2025, CarMax disclosed significant year-over-year declines in revenue and profit, including a 6.0% revenue decline, a 7.2% decline in total retail used vehicle revenues, and a 5.6% decline in total gross profit, attributed to inventory adjustments and a $71.3 million increase in loan loss provisions, resulting in a further stock price drop of $11.45 (20.1%) to $45.60 [6]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Avita Medical, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1]. Investigation Details - The investigation is focused on whether Avita has engaged in practices that may have harmed investors, particularly in light of recent financial disclosures [2]. Financial Performance - On August 7, 2025, Avita reported a significant backlog in unpaid provider claims for its Recell procedures, which negatively impacted demand in the first half of the year. The backlog was attributed to delays in pricing determinations by contractors from the Centers for Medicare & Medicaid Services [6]. - The accumulation of unpaid claims led to uncertainty among providers, resulting in a reduction of Recell utilization during the first half of 2025 [6]. - Following the announcement of these issues, Avita's stock price fell by $1.13, or approximately 21%, from $5.38 to $4.25 per share [6].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Six Flags Entertainment Corporation due to disappointing financial results and possible violations of federal securities laws [1][3]. Financial Performance - On August 6, 2025, Six Flags reported a reduction in its EBITDA guidance for the year to between $860 million and $910 million, down from a previous expectation of $1.08 billion to $1.12 billion [3]. - The downgrade in guidance is attributed to several factors, including first-half results, a smaller season-pass base, and economic volatility affecting customer behavior [3]. Stock Market Reaction - Following the announcement of the disappointing results, Six Flags' stock price fell by $6.38 per share, or 20.78%, closing at $24.32 per share on August 6, 2025 [4]. Management Changes - Six Flags' President and CEO, Richard Zimmerman, is set to step down from his roles by the end of the year, which may further impact investor confidence [3].

Core Insights - Coty Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results for fiscal year 2025 [2][3] - The company reported an unexpected loss and provided poor guidance, attributing sluggish sales to various market challenges [3] - Following the announcement, Coty's stock price dropped by $1.05, or 21.6%, closing at $3.81 per share [4] Financial Performance - Coty reported its full fiscal year 2025 and fourth-quarter results on August 20, 2025, highlighting an unexpected loss [3] - The Chief Financial Officer indicated that the challenges faced in fiscal year 2025 were linked to a broader decline in profit within the beauty market [3] Market Reaction - The announcement of the financial results led to a significant decline in Coty's stock price, reflecting investor concerns [4]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Fluor Corporation for possible violations of federal securities laws and unlawful business practices following disappointing quarterly earnings and a significant stock price drop [1][3]. Financial Performance - On August 1, 2025, Fluor reported quarterly earnings of 43 cents per share on revenue of $3.98 billion, missing analysts' expectations of 55 cents per share on $4.51 billion revenue [3]. - The company revised its full-year earnings guidance down to $1.95 - $2.15 per share from a previous range of $2.25 to $2.75 per share [3]. Stock Market Reaction - Following the earnings report, Fluor's stock price fell by $16.40, opening at $40.37 per share [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Fluor Corporation due to reported losses and possible violations of federal securities laws [1][3]. Financial Performance - On August 1, 2025, Fluor reported quarterly earnings of 43 cents per share on revenue of $3.98 billion, missing street estimates of 55 cents per share on $4.51 billion revenue [3]. - The company has revised its full-year earnings guidance down to $1.95 - $2.15 per share, from a previous range of $2.25 to $2.75 per share [3]. Stock Market Reaction - Following the earnings report, Fluor's stock price dropped by $16.40, opening at $40.37 per share [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Anika Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices following disappointing clinical trial results for its product Hyalofast [1][3]. Company Summary - Anika Therapeutics, Inc. (NASDAQ: ANIK) recently announced topline results from a pivotal clinical trial of Hyalofast, which is a resorbable hyaluronic acid scaffold for cartilage repair. The trial showed improvements in treated patients but did not meet its pre-specified co-primary endpoints due to a higher dropout rate and missed visits during COVID-19 [3]. - Following the announcement of the trial results, Anika's stock price dropped by $3.06, or 27.42%, closing at $8.10 per share on July 30, 2025 [3]. Legal Investigation - The law firm Bragar Eagel & Squire, P.C. is encouraging investors who suffered losses from Anika's stock to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether Anika has engaged in unlawful business practices that may have affected its stockholders [1]. Contact Information - Investors can reach out to Bragar Eagel & Squire, P.C. for inquiries regarding the investigation through phone or email [4][7].